Stocks Profile

Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for the treatment of cancer. It is developing pixantrone, a Phase III single-agent clinical trial product for the treatment of non-Hodgkins lymphoma and various other hematologic malignancies, solid tumors, and immunological disorders; OPAXIO, a Phase III clinical trial product for the treatment of ovarian, esophageal, and non-small cell lung cancer; and brostallicin, a Phase I/II clinical trials product for the treatment of sarcoma.

Full post…